Background: Addiction to alcohol and nicotine remains a global health challenge, with current treatment options often hindered by issues of frequent dosing and low patient adherence. Transdermal drug delivery systems, such as microneedle patches, offer a promising solution to overcome these limitations by enabling controlled and sustained drug release. The aim of the study: To optimize and characterize microneedle patches for the transdermal delivery of Naltrexone HCl and Nicotine USP to support alcohol and smoking cessation. The goal is to enhance treatment efficacy and patient adherence through advanced drug delivery systems. Materials and methods: The research began with preformulation analyses to assess the solubility, thermal behaviour, and structural integrity of the drugs, ensuring their suitability for incorporation into microneedle patches. Various formulations were developed, varying the concentrations of Polyvinylpyrrolidone (PVP) and incorporating 3% Tween 80 as a permeation enhancer. In vitro studies were conducted to evaluate drug release profiles and permeation capabilities. Results: Microneedle patches demonstrated significant cumulative drug permeation, highlighting their potential for effective transdermal delivery. Formulations with reduced PVP ratios exhibited slower drug release rates. However, the addition of 3% Tween 80 successfully enhanced drug release, achieving complete drug permeation over time. These findings underscore the patches' ability to provide controlled release while maintaining structural integrity. Conclusion: The optimized microneedle patches present a novel approach to managing alcohol and nicotine addiction by addressing challenges related to frequent dosing and adherence. By improving drug delivery efficiency and patient compliance, these systems hold significant potential to enhance the success of addiction treatment strategies